Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals 4/28/2025 Earnings Report

Hemogenyx Pharmaceuticals logo
GBX 180.50 -1.75 (-0.96%)
As of 04/29/2025 12:30 PM Eastern

Hemogenyx Pharmaceuticals EPS Results

Actual EPS
-GBX 181.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hemogenyx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hemogenyx Pharmaceuticals Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Hemogenyx Pharmaceuticals Earnings Headlines

Top performing AI play of the decade…? (The answer will shock you)
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.
Hemogenyx Pharmaceuticals Announces Key Corporate Changes
See More Hemogenyx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hemogenyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hemogenyx Pharmaceuticals and other key companies, straight to your email.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals (LON:HEMO), a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

View Hemogenyx Pharmaceuticals Profile

More Earnings Resources from MarketBeat